NextCure (NXTC)
Developing antibody-drug conjugate candidates for difficult-to-treat cancers.
$7.35
Pre-market−0.05 (−0.68%)
At close$7.40(+8.82%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions26 holders · as of Mar 31, 2026 | 60.06% | 2.17M shares | |
| Strategic holders2 holders · as of Aug 14, 2026 | 28.54% | 1.03M shares | |
| Otherremainder | 11.40% | 411.6K shares |
3.61M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (4.58M in the company's Sep 3, 2026 report, 3.61M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
26 holders · 2.17M shares · 7 new positions · 10 increased · 4 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Squadron Capital Management LLC | 265.0K | 7.34% | +28.0K | May 15, 2026 |
| Affinity Asset Advisors, LLC | 241.8K | 6.69% | −5.5K | May 14, 2026 |
| Ikarian Capital, LLC | 238.3K | 6.60% | 0 | May 15, 2026 |
| Sofinnova Investments, Inc. | 222.7K | 6.16% | 0 | May 15, 2026 |
| Silverarc Capital Management, LLC | 176.1K | 4.87% | 0 | May 14, 2026 |
| Vanguard Capital Management LLC | 160.5K | 4.44% | +160.5Knew | May 15, 2026 |
| Pfizer Inc | 153.4K | 4.25% | −4.3K | May 12, 2026 |
| Opaleye Management Inc. | 141.2K | 3.91% | +141.2Knew | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 15.80% | 722.4K | 13G | Aug 14, 2026 ↗ |
| Logos Global Management GP LLCincl. Logos GP LLC, Arsani William +2 more | 11.00% | 13G/A | Nov 14, 2024 ↗ | |
| Ikarian Capital, LLC | 9.99% | 363.0K | 13G | Feb 17, 2026 ↗ |
| Affinity Asset Advisors, LLC | 9.99% | 348.6K | 13G | Jan 29, 2026 ↗ |
| Squadron Master Fund LP | 9.90% | 271.1K | 13G | Feb 17, 2026 ↗ |
| Simcere Zaiming, Inc. | 9.40% | 338.6K | 13G | May 6, 2026 ↗ |
| Adage Capital Management, L.P. | 7.67% | 277.2K | 13G | Aug 12, 2026 ↗ |
| Affinity Healthcare Fund, LP | 7.17% | 191.9K | 13G | Nov 14, 2025 ↗ |
| Sofinnova Venture Partners IX, L.P. ("SVP IX")incl. Dr. James I. Healy ("Healy"), Sofinnova Management IX, L.L.C. ("SM IX") | 7.10% | 222.7K | 13D | Mar 5, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 10, 2026 | Simcere Zaiming, Inc.other: Former 10% Owner | Sale | 30,000 | $6.16 | 308,636 |
| Jul 30, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase · 5 lots | 272,850 | $4.93 | 686,116 |
| Jul 31, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase · 3 lots | 36,303 | $4.94 | 722,419 |
| Jul 27, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 7,798 | $5.00 | 383,456 |
| Jul 28, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 6,400 | $4.95 | 389,856 |
| Jul 29, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase · 2 lots | 3,410 | $5.00 | 393,266 |
CongressHouse and Senate disclosures
Not reported.